miR-33 Nucleic Acid Suppresses TDP-43 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating TDP-43 proteinopathy, a neurodegenerative disease characterized by the aggregation of TDP-43 protein, are limited as they primarily focus on reducing protein levels through degradation rather than addressing the overexpression, and there is a lack of effective microRNAs targeting the TDP-43 gene to regulate its expression.
Innovation Solution
Identification and utilization of miR-33, a microRNA that targets the TDP-43 gene, to suppress its expression, thereby correcting the imbalance and reducing the vulnerability of neurons associated with TDP-43 overexpression, using nucleic acids encoding miR-33 or its variants, potentially delivered via virus vectors or nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TDP-43 protein levels are increased to treat neurodegenerative diseases, then neuronal protection should be improved, but TDP-43 aggregation and cytotoxicity worsen
Solution Approach 1:
The patent changes the regulatory parameter by introducing microRNA molecules that specifically target TDP-43 mRNA for degradation. This shifts the control mechanism from protein level modulation to transcript level control, allowing precise downregulation of TDP-43 expression to prevent aggregation while maintaining sufficient functional protein levels for neuronal protection
Solution Approach 2:
The patent uses microRNAs as intermediary molecules to mediate the regulation of TDP-43 expression. These microRNAs act as intermediaries between the therapeutic intervention and the TDP-43 protein, providing controlled suppression of TDP-43 mRNA translation and stability without directly affecting the protein itself
2Object-affected harmful factors
If existing therapeutic methods are used to reduce TDP-43 protein levels, then protein aggregation should be decreased, but the underlying overexpression mechanism is not addressed
Solution Approach 1:
The patent applies preliminary action by targeting TDP-43 mRNA before it is translated into protein. By degrading the mRNA transcript through microRNA-mediated mechanisms, the invention prevents the formation of excessive TDP-43 protein in the first place, addressing the root cause of overexpression rather than merely clearing aggregated protein after formation
Solution Approach 2:
The patent replaces mechanical/proteolytic degradation systems with a nucleic acid-based regulatory system. Instead of relying on proteasomes or autophagy to degrade aggregated proteins, the invention uses microRNA-directed mRNA degradation to prevent protein synthesis at the transcriptional level, substituting a more upstream and controllable mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of miR-33 effectively suppresses TDP-43 expression, ameliorating the pathological properties in motor neurons by restoring the balance between TDP-43 and miR-33 levels, offering a prophylactic or therapeutic approach for TDP-43 proteinopathy.
Implementation Method 1
a microRNA forming a miRNA-RISC complex binds to a 3'UTR of a particular mRNA, and thereby causes degradation or translational inhibition of the mRNA
Data Source
AI summary
The present invention aims to provide a composition for the prevention or treatment of TDP-43 proteinopathy using a microRNA targeting the TDP-43 gene.A prophylactic or therapeutic composition for TDP-43 proteinopathy, comprising: one or more nucleic adds selected from the group consisting of isolated RNAs and isolated nucleic acids encoding the RNAs, wherein the RNAs consist of human miR-33 represented by SEQ ID NO: 1, variants of the human miR-33 having one or more mutations, and precursors of the human miR-33 and the variants.